Page 7 - Jared Gollob News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Kymera Therapeutics Presents Clinical Data from the Phase 1 Trial of IRAK4 Degrader, KT-474 (SAR444656), at the European Academy of Dermatology and Venereology Symposium

In the Phase 1 trial, KT-474 showed evidence of robust IRAK4 degradation in blood and skin lesions as well as a systemic anti-inflammatory effect in hidradenitis suppurativa and atopic dermatitis . | May 18, 2023

United statesHidradenitis suppurativaTodd cooperBruce jacobsChris brinzeyJared gollobCorporate affairsExchange commissionEuropean academy of dermatologyKymera therapeutics incBoston globeEuropean academyChief medical officerFierce biotechBoston business journalPrivate securities litigation reform act

Kymera Therapeutics, Inc (NASDAQ:KYMR) Q4 2022 Earnings Call Transcript

Operator: Hello, and welcome to the Kymera Therapeutics Fourth Quarter 2022 Earnings Conference Call. Please note, this event is being recorded.

United statesKalpit patelMike kratkyAndrew fleszarPaul jengRaymond jamesRebecca mosherDerek archilaBruce jacobsVikram purohitZhi shuMarc frahmJohn reedZhiqiang shuJared gollobNello mainolfi

Royal Bank of Canada Boosts Stock Holdings in Kymera Therapeutics, Inc (NASDAQ:KYMR)

Royal Bank of Canada Boosts Stock Holdings in Kymera Therapeutics, Inc (NASDAQ:KYMR)
etfdailynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from etfdailynews.com Daily Mail and Mail on Sunday newspapers.

United statesNello mainolfiJared gollobMorgan stanleySecurities exchange commissionPrincipal financial group incZacks investment researchLazard asset managementExchange commissionFirst mercantile trust coKymera therapeutics incAmeritas investment partners incRoyal bankKymera therapeuticsAsset managementMercantile trust

Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021

Kymera Therapeutics Presents Late-Breaking Preclinical Data Highlighting Superiority of Dual-Targeting Activity of IRAKIMiD Degrader KT-413 at AACR Annual Meeting 2021
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPaul coxNello mainolfiJared gollobExchange commissionKymera therapeutics incDrug administrationAmerican association of cancer researchLissettel steeleverge scientific communications for kymeraAmerican associationCancer researchAnnual meetingInvestigational new drug applicationChief medical officerKymera therapeuticskymera therapeuticsNote regarding forward looking statementsthis